William Blair Issues Positive Forecast for APLS Earnings

Key Points

• William Blair has raised its Q4 2025 earnings estimate for Apellis Pharmaceuticals to ($0.22) per share, reflecting an improvement from the previous estimate of ($0.25) per share.
• The average stock rating for Apellis Pharmaceuticals is currently a Moderate Buy, with a consensus target price of $40.26, despite varying opinions from other brokerages.
• Recent insider trading shows significant sales, with General Counsel David O. Watson and CEO Cedric Francois selling shares valued at approximately $496,392.25 combined.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities research analysts at William Blair boosted their Q4 2025 EPS estimates for shares of Apellis Pharmaceuticals in a research report issued to clients and investors on Tuesday, July 29th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings of ($0.22) per share for the quarter, up from their prior estimate of ($0.25). The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. William Blair also issued estimates for Apellis Pharmaceuticals' Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at $0.08 EPS and FY2026 earnings at ($0.52) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.11. The firm had revenue of $171.39 million during the quarter, compared to analyst estimates of $187.91 million. Apellis Pharmaceuticals had a negative net margin of 30.24% and a negative return on equity of 116.09%. The business's revenue for the quarter was down 10.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.30) EPS.

APLS has been the subject of several other reports. Wall Street Zen raised shares of Apellis Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday. Cantor Fitzgerald upped their price objective on shares of Apellis Pharmaceuticals from $39.00 to $40.00 and gave the company an "overweight" rating in a research note on Friday. Royal Bank Of Canada upped their price objective on shares of Apellis Pharmaceuticals from $17.00 to $19.00 and gave the company a "sector perform" rating in a research note on Friday. Wells Fargo & Company upped their price objective on shares of Apellis Pharmaceuticals from $26.00 to $29.00 and gave the company an "equal weight" rating in a research note on Monday, June 2nd. Finally, Scotiabank lowered their price objective on shares of Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating for the company in a research note on Thursday, May 8th. Ten analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $37.78.

Apellis Pharmaceuticals Price Performance

NASDAQ:APLS traded up $1.06 during midday trading on Thursday, hitting $24.01. The company had a trading volume of 1,869,194 shares, compared to its average volume of 2,280,599. Apellis Pharmaceuticals has a 52-week low of $16.10 and a 52-week high of $41.94. The stock's fifty day moving average price is $18.76 and its 200-day moving average price is $21.73. The company has a market capitalization of $3.02 billion, a PE ratio of -13.20 and a beta of 0.77. The company has a quick ratio of 3.16, a current ratio of 3.77 and a debt-to-equity ratio of 2.90.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Assetmark Inc. grew its stake in shares of Apellis Pharmaceuticals by 3,938.7% in the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company's stock worth $27,000 after buying an additional 1,221 shares in the last quarter. Parallel Advisors LLC grew its stake in shares of Apellis Pharmaceuticals by 80.0% in the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company's stock worth $33,000 after buying an additional 855 shares in the last quarter. GF Fund Management CO. LTD. boosted its stake in shares of Apellis Pharmaceuticals by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company's stock worth $70,000 after purchasing an additional 573 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Apellis Pharmaceuticals by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company's stock worth $84,000 after purchasing an additional 655 shares during the period. Finally, Covestor Ltd boosted its stake in shares of Apellis Pharmaceuticals by 1,819.2% during the 4th quarter. Covestor Ltd now owns 3,992 shares of the company's stock worth $127,000 after purchasing an additional 3,784 shares during the period. 96.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 19,725 shares of Apellis Pharmaceuticals stock in a transaction on Thursday, July 17th. The shares were sold at an average price of $20.21, for a total value of $398,642.25. Following the sale, the chief executive officer directly owned 331,605 shares in the company, valued at approximately $6,701,737.05. The trade was a 5.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel David O. Watson sold 5,000 shares of Apellis Pharmaceuticals stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $19.55, for a total transaction of $97,750.00. Following the completion of the sale, the general counsel owned 128,730 shares in the company, valued at approximately $2,516,671.50. This represents a 3.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 169,090 shares of company stock worth $3,403,832 over the last 90 days. Insiders own 6.50% of the company's stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).